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An atom-eﬃcient and convergent approach to the
preparation of NS5A inhibitors by C–H activation†
Thomas O. Moore,* Michael Paradowski and Simon E. Ward
A novel approach of the convergent functionalisation of aryl dibromides to form NS5A type inhibitors
using C–H activation is reported. The focus of investigation was to reduce the formation of homodimeric
side product, as well as to investigate the scope of diﬀerent aryl dibromides that were tolerated under the
reaction conditions. The C–H activation methodology was found to give a viable synthetic route to NS5A
inhibitors, with late stage functionalisation of the core portion of the molecule, albeit with some chemical
functionalities not tolerated.
Introduction
The hepatitis C virus (HCV) is estimated to aﬀect 170 million
people worldwide and, without treatment, may lead to cirrho-
sis, hepatocellular carcinoma, liver failure and ultimately
death.1–4 Until recently, the standard of care for HCV patients
was a combination of lengthy regimens of pegylated interferon
α (pegIFN-α) and ribavirin.5 Those poorly tolerated and mode-
rately eﬃcacious therapies contributed to the urgent need to
identify improved treatments by oral administration. One
major focus to achieve this was targeted at the nonstructural
protein 5A (NS5A) which is enabled in the HCV genome and
plays an essential role for the viral RNA replication.6–8 Those
eﬀorts led to the discovery of daclatasvir (BMS) (Fig. 1), a non
‘rule of 5’ compliant NS5a inhibitor exhibiting picomolar
activity against HCV genotypes 1a and 1b.9 Subsequently, there
have been over 70 patents and publications describing novel
NS5A inhibitors related to Daclatasvir.9–14 Of these, many have
maintained its symmetrical biphenylimidazole core with
diﬀerentiation arising from key structural aryl alterations.15–18
The existing strategy for the preparation of dimeric NS5A
inhibitors is by chain elongation from an aryl bis acetate core.
However, this methodology is linear and does not allow rapid
exploration of the central core unit. A number of reports and
patents have also described the preparation of symmetrical
aryl-imidazoles by a late stage cross coupling of bis-metalated
aryl core to the required halogenated imidazole fragments.17–20
This methodology oﬀers the advantage of a late diversification
of the central core units but suﬀers from the lengthy, expens-
ive and poor atom-eﬃcient processes to install the pre-
requisite organometallic reagents. However, to the best of our
knowledge, none of the late stage cross coupling methodo-
logies reported had the key pharmacophores comprising of a
pair of (S)-methoxycarbonylvaline capped pyrrolidines already
in place and required further synthetic steps to prepare the
reported NS5A inhibitors.
Our search for methodology that allowed us to form this
bond as late as possible highlighted the opportunity to con-
sider a double C–H activation strategy. The C–H activation of
imidazoles in the desired C-5 position is one that has under-
gone much development in recent years.21–25 Arguably the key
development was the establishment of broadly applicable con-
ditions for the C–H activation of heterocycles by Fagnou,24
where the use of pivalic acid as an additive was found to
greatly increase the rate and overall yield of reaction due to
transition state stabilisation.26 Given that the SEM group has
been found to be well tolerated under C–H activation con-
ditions,27 a synthetic route based around the reaction between
SEM-protected imidazoles and aryl dibromides was developed.
Results and discussion
N-Boc-L-prolinal 3 was obtained from the corresponding proli-
nol 2 under mild copper/TEMPO mediated aerobic oxidation
conditions (Scheme 1). Although the Swern oxidation con-
ditions gave 3 in quantitative yields, we had concerns about
Fig. 1 Structure of daclatasvir.
†Electronic supplementary information (ESI) available. See DOI: 10.1039/
c6ob00340k
Sussex Drug Discovery Centre, University of Sussex, Brighton, England BN1 9QJ, UK.
E-mail: T.Moore@sussex.ac.uk
This journal is © The Royal Society of Chemistry 2016 Org. Biomol. Chem., 2016, 14, 3307–3313 | 3307
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
5 
Fe
br
ua
ry
 2
01
6.
 D
ow
nl
oa
de
d 
on
 2
2/
02
/2
01
8 
11
:3
0:
00
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
View Journal  | View Issue
the potential racemisation of the carbonyl α-carbon due to the
presence of triethylamine, and thus opted for milder con-
ditions on scale up. Cyclisation of the prolinal 3 under glyoxal
and ammonia conditions followed by removal of the BOC pro-
tecting group gave pyrrolidine 5 in 85% yield over three steps.
Methyl carbamate-L-valine 6, obtained via reported Schotten–
Bauman conditions from L-valine,28 was then coupled to
imidazole pyrrolidine 5 by peptide bond formation, although
this proved challenging due to high aqueous solubility of the
product formed and its instability when purified by silica
chromatography. Mild coupling reagents such as guanidinium
salts and carbodiimides were found to be unsuitable mainly
due to the diﬃculty separating the product and byproducts
formed. The respective acid chloride was found to react cleanly
with pyrrolidine 5, however we were concerned with the possi-
bility of ketene formation from HCl elimination, leading to
racemisation of the chiral valyl carbon as reported by Sauer.29
Pyridine was used instead of triethylamine to reduce the likeli-
hood of racemisation and gave 7 in 97% yield. D-Valine-carb-
amate was also coupled with 5 and both NMR and HPLC
experiments confirmed the lack of racemisation under the
reaction conditions. Subsequent protection of imidazole 7
with 2-(trimethylsilyl)ethoxymethyl (SEM) chloride in THF
with sodium hydride as a base gave the key C–H activation
precursor 8 in 47% yield.
Pleasingly, 10 was obtained in moderate yields on first
attempt by double C–H activation of 8 with 4-4′-dibromobiphenyl
under the conditions reported by Fagnou (Pd(dppf)Cl2, PivOH,
DMA, 100 °C, 4 h, Table 1).24 Unfortunately however a homo-
coupled by-product 11 was produced, which proved diﬃcult to
separate from the product by standard purification techniques.
In proof of concept studies on a simplified imidazole reagent
carried out by our group, it was shown that optimisation of
conditions focusing on the base, solvent and reaction tempera-
ture had the greatest eﬀect on formation of this homo-coupled
by-product. We therefore set about modifying these conditions
to test whether it was possible to prevent any by-product for-
mation. It was found that the previously established con-
ditions30 were not only the highest yielding, but also exhibited
very low amounts of homo-coupled product by LCMS analysis.
When the reaction was carried out in dioxane at 100 °C, or in
DMA at 60 °C (Table 1, entries 2 and 6), no homo-coupled
product was observed by LCMS, but the drop in overall yield
and rate of reaction in both of these cases made them imprac-
tical. As such, the Fagnou conditions were deemed the best
suited for use in the double C–H activation. The 78% yield
observed by LCMS for condition 5 equated to an 84% yield
upon scale up and purification by column chromatography.
Scheme 1 Preparation of the key (S)-methoxycarbonylvaline capped pyrrolidine 7.
Table 1 Optimisation conditions for the C–H activation
Entry Base Solvent Temperature Yield 9a 10 : 9a
1 K2CO3 DMF 100 °C 65% 0.13
2 K2CO3 Dioxane 100 °C 10% 0
3 K2CO3 NMP 100 °C 38% 0.05
4 K2CO3 THF 100 °C 25% 0.11
5 K2CO3 DMA 100 °C 78% 0.03
6 K2CO3 DMA 60 °C 1% 0
7 K2CO3 DMA 80 °C 5% 0.15
8 K2CO3 DMA 120 °C 69% 0.07
9 Cs2CO3 DMA 100 °C 21% 0.10
10 KOAc DMA 100 °C 3% 0.23
11 K3PO4 DMA 100 °C 72% 0.06
a Yield of 9 and ratio of 10 : 9 determined by LCMS peak integration
measured by adsorption at 254 nm. Conditions: (i) Pd(dppf)Cl2,
PivOH, base, 4 hours.
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Removal of the SEM protecting group post C–H activation
using organic solubilised fluoride ions proved unsuccessful
even at elevated temperatures and extended reaction times.
However, conditions involving trifluoroacetic acid at room
temperature cleaved the SEM group slowly but in quantitative
yield (Scheme 2). Despite some initial stability concerns, the
methyl carbamate functionality proved to be stable under the
TFA deprotection conditions.
With the synthesis for 1 optimised, we turned our attention
to the scope of this methodology for the rapid synthesis of
potential symmetrical NS5A inhibitors (Table 2). Under the
reaction conditions developed above, bis-CH activated pro-
ducts were obtained in moderate to good yields over 2 steps.
Purification of deprotected product was carried out by prep-
scale LCMS mass directed auto purification, giving better
separation of the product and homo-dimer by-product.
Overall, of 16 diﬀerent aryl dibromides tested, 9 successfully
underwent double C–H activation. The yields of successful
couplings consistently ranges from moderate to good on a
0.1 mmol scale. The proportion of homo-dimer to product,
however, was found to vary greatly, with a tendency to be
highest in electron rich aryl di-bromides, such as entries 4
and 7.
Several functional groups were found to not be compatible
with the reaction conditions used. The presence of an alkyne
(entry 5) seemed to prevent formation of the anticipated
product, and instead produced many unidentifiable side-
products. Coordination of alkynes to palladium centres through
an η-2 binding mode is well precedented to undergo a wide
variety of reactions, and as such this seems likely to be respon-
sible for the lack of desired reactivity observed.31 Aryl di-
bromides containing a 2-phenylpyridine (entries 6 and 15)
functionality also did not allow the reaction to proceed as
hoped, with the reaction mixture containing starting materials
and a mixture of side products after prolonged heating. There
is much precedent for the C–H activation directing capability
of pyridyl nitrogen’s onto 2-phenyl groups,32 possibly account-
ing for the loss of desired reactivity, however there was no
identifiable side product proving this hypothesis. Further-
more, no reaction was observed in the presence of aryl di-
bromides containing an N–H functionality (entries 11, 12, 14
and 16). However, when the amide group in entry 12 was
Table 2 Scope of double C–H activation
Entry Aryl dibromide Yielda (%) HD : Pb
1 78% 0.13
2 80% 0
3 64% 0.37
4 37% 0.72
5 0% —
6 0% —
7 42% 0.68
8 67% 0.12
9c 45% 0.26
10c 58% 0.23
11 0% —
12 0% —
13 67% 0
14 0% —
Scheme 2 Deprotection step under protolytic conditions.
Organic & Biomolecular Chemistry Paper
This journal is © The Royal Society of Chemistry 2016 Org. Biomol. Chem., 2016, 14, 3307–3313 | 3309
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
5 
Fe
br
ua
ry
 2
01
6.
 D
ow
nl
oa
de
d 
on
 2
2/
02
/2
01
8 
11
:3
0:
00
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
masked with an N-methyl functionality the reaction proceeded
well (entry 13). This is particularly surprising considering the
presence of a carbamate N–H bond within the imidazole start-
ing material, which is tolerated in the reaction conditions.
Subsequent deprotection under TFA conditions led to the
preparation of the NS5A-like analogues. To our surprise, the
furan and thiophene (entries 9 and 10) were found to decom-
pose upon exposure to TFA during the deprotection. As they
were also found to be unreactive towards milder TBAF con-
ditions, they were purified and characterised as the SEM-
protected analogue instead.
Conclusions
In summary, we have described a novel, green and eﬃcient
approach to the synthesis of symmetrical NS5A-like com-
pounds such as daclatasvir. The overall synthesis was accom-
plished using a novel double C–H activation as a key step that
allows for a rapid synthesis of analogues and late stage struc-
tural diversification, which is to our knowledge the first time
that palladium catalysed C–H activation has been used to con-
struct symmetrical molecules in such a way. However, we
found that intolerance of some co-ordinating functionalities in
the reaction conditions gave some limitation to the methodo-
logy, and this must be considered when hoping to attempt this
strategy.
Experimental section
General procedure for C–H activated cross coupling for
compound without deprotection
The appropriate aryl dibromide (0.10 mmol), (S)-tert-butyl 2-(1-
((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-2-yl)pyrrolidine-
1-carboxylate (7, 100 mg, 0.240 mmol), pivalic acid (6.1 mg,
0.060 mmol), K2CO3 (41 mg, 0.30 mmol) and Pd(ddpf)Cl2
(7.3 mg, 0.010 mmol) were placed in a sealed reaction vial. The
reaction vial was placed under reduced pressure then purged
with nitrogen, repeating the process 5 times. The contents of
the sealed vial were dissolved in dimethylacetamide (1 mL),
and the solvent was deoxygenated by bubbling with nitrogen
for 20 minutes. The solution was then irradiated in a micro-
wave at 100 °C for 4 hours. The resulting solution was
quenched with water (15 mL), and extracted with EtOAc
(2 × 10 mL). The organic phase was washed with concentrated
sodium bicarbonate solution (2 × 15 mL) water (2 × 15 mL),
and brine (2 × 15 mL), before being concentrated to a solid
under reduced pressure. This solid was then purified to the
desired product by mass-directed auto purification.
Dimethyl(2S,2′S)-1,1′-((2S,2′S)-2,2′-(5,5′-(biphenyl-4,4′-diyl)
bis(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-5,2-diyl))
bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl)
dicarbamate (10). 1H NMR (500 MHz, CD3OD) 7.79 (4H, d,
J 7.8 Hz, ArH), 7.59 (4H, d, J 7.9 Hz, ArH), 7.04 (2H, s, ArH),
5.79 (2H, d, J 10.9 Hz, CH2), 5.32 (2H, d, J 10.9 Hz, CH2), 5.24
(2H, s, CH), 4.22 (2H, d, J 7.5 Hz, CH), 4.11–4.03 (2H, m, CH2),
3.95–3.86 (2H, m, CH2), 3.66 (6H, s, CH3), 3.61–3.44 (4H, m,
CH2), 2.37 (4H, m, CHAB), 2.21–1.96 (6H, m, CHAB), 0.90 (16H,
m, CH2, CH3), −0.03 (18H, s, Si(CH3)3); 13C NMR (126 MHz,
CD3OD) 171.7 (CO), 158.0, OC(O)N), 150.9 (NCN), 140.0 (ArC),
133.1 (ArC), 129.4 (ArCH), 128.8 (ArC), 127.0 (ArCH), 125.4
(ArCH), 72.1 (CH2), 65.6 (CH2), 58.3 (CH), 53.2 (CH), 51.3
(CH3), 47.6 (CH2), 31.6 (CH2), 30.1 (CH), 24.7 (CH2), 18.4
(CH3), 17.30 (CH2), −2.84 (Si(CH3)3); IR (neat, νmax, cm−1) 3276
(bw), 2959 (m), 1719 (s), 1631 (s), 1507 (m), 1441 (s), 1248 (s),
1189 (m), 1178 (s), 1033 (m), 820.21 (s), 693 (m); HRMS (ESI):
calcd for C52H78N8Na1O8Si2 [M + H]
+ 1021.5368, found
1012.5373; [α]D −39.4 (c 0.6 in CHCl3, T 21.0 °C).
Dimethyl((2S,2′S)-((2S,2′S)-2,2′-(5,5′-(furan-2,5-diylbis(4,1-
phenylene))bis(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imid-
azole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-
2,1-diyl))dicarbamate (12). 1H NMR (500 MHz, CDCl3) δ 7.80
(4H, d, J 8.0 Hz, ArH), 7.49 (4H, d, J 8.1 Hz, ArH), 7.05 (2H, s,
FurylH), 6.82 (2H, s, ArH), 5.79 (2H, d, J 10.6 Hz, CH2), 5.29
(2H, d, J 9.1 Hz, NH), 5.24–5.16 (4H, m, CHAB, CH), 4.35 (2H,
dd, J 9.2, 6.4 Hz, CH), 3.98–3.87 (4H, m, CH2), 3.67 (6H, s,
CH3), 3.59–3.46 (4H, m, CH2), 2.55–2.42 (2H, m, CHAB),
2.39–2.26 (4H, m, CH2), 2.15–1.91 (4H, m, CHAB, CH),
1.01–0.87 (10H, m, CH3, CH2), 0.80 (6H, d, J 6.7 Hz, CH3), 0.00
(18H, s, Si(CH3)3);
13C NMR (126 MHz, CDCl3) δ 170.9 (CO),
157.1 (OC(O)N), 153.3 (ArC), 151.6 (ArC), 150.7 (ArC), 133.8
(ArC), 132.8 (ArC), 129.3 (ArCH), 124.0 (ArCH), 108.0 (ArCH),
88.3 (FurylCH), 65.9 (CH2), 57.6 (CH), 52.9 (CH), 52.2 (CH3),
47.6 (CH2), 31.8 (CH2), 31.1 (CH), 25.2 (CH2), 19.3 (CH3), 18.0
Table 2 (Contd.)
Entry Aryl dibromide Yielda (%) HD : Pb
15 0% —
16 0% —
a Yield of product determined by LCMS peak integration measured by
adsorption at 254 nm. Characterisation was carried out on the fully
deprotected product (see Experimental section). b Ratio of homo-dimer
to product. c Product decomposed under deprotection and
characterisation was carried out on the SEM-protected product.
Paper Organic & Biomolecular Chemistry
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(CH2), 17.3 (CH3), −1.4 (Si(CH3)3); IR (neat, νmax, cm−1) 2955
(m), 1719 (s), 1640 (s), 1503 (m), 1440 (m), 1249 (s), 1188 (m),
1082 (s), 1030 (w), 837 (s), 697 (w); HRMS (ESI): calcd
for C56H81N8O7Si2 [M + H]
+ 1065.5660, found 1065.5642;
[α]D −102.1 (c 0.3 in CHCl3, T 22.5 °C).
Dimethyl((2S,2′S)-((2S,2′S)-2,2′-(5,5′-(thiophene-2,5-diylbis-
(4,1-phenylene))bis(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imid-
azole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-
2,1-diyl))dicarbamate (13). 1H NMR (500 MHz, CDCl3) δ 7.71
(4H, d, J 7.8 Hz, ArH), 7.47 (4H, d, J 8.0 Hz, ArH), 7.38 (2H, s,
thiopheneH), 7.12 (2H, s, ArH), 5.81 (2H, d, J 10.6 Hz, CHAB),
5.29–5.14 (6H, m, CHAB, CH, NH), 4.39–4.31 (2H, m, CH),
4.21–4.05 (2H, m, CHAB), 3.99–3.84 (2H, m, CHAB), 3.66 (6H, s,
CH3), 3.59–3.43 (4H, m, CH2), 2.58–2.28 (6H, m, CHAB, CH2),
2.17–1.93 (4H, m, CHAB, CH), 1.01–0.85 (10H, m, CH3, CH2),
0.79 (6H, d, J 6.7 Hz, CH3), 0.00 (18H, s, Si(CH3)3);
13C NMR
(126 MHz, CDCl3) δ 171.4 (CO), 157.1 (OC(O)N), 150.3 (NCN),
143.2 (ArC), 134.5 (ArC), 134.1 (ArC), 132.9 (ArC), 129.7 (ArCH),
125.9 (ArCH), 124.8 (thiopheneCH), 118.4 (ArCH), 72.9 (CH2),
66.4 (CH2), 57.7 (CH), 52.8 (CH), 52.2 (CH3), 47.7 (CH2), 31.7
(CH2), 30.6 (CH), 25.4 (CH2), 19.4 (CH3), 18.0 (CH2), 17.2
(CH3), −1.4 (Si(CH3)3); IR (neat, νmax, cm−1) 3681 (bw), 2967
(m), 2844 (m), 1718 (m), 1637 (m), 1508 (w), 1455 (m), 1429
(m), 1055 (s), 1033 (s), 1015 (s), 838 (m); HRMS (ESI): calcd
for C56H81N8O6Si2S [M + H]
+ 1081.5431, found 1081.5449;
[α]D −69.1 (c 1.2 in CHCl3, T 22.7 °C).
General procedure for C–H activated cross coupling and
subsequent SEM-removal
The appropriate aryl dibromide (0.10 mmol), (S)-tert-butyl 2-(1-
((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-2-yl)pyrrolidine-
1-carboxylate (7, 100 mg, 0.240 mmol), pivalic acid (6.1 mg,
0.060 mmol), K2CO3 (41 mg, 0.30 mmol) and Pd(ddpf)Cl2
(7.3 mg, 0.010 mmol) were placed in a sealed reaction vial. The
reaction vial was placed under reduced pressure then purged
with nitrogen, repeating the process 5 times. The contents of
the sealed vial were dissolved in dimethylacetamide (1 mL),
and the solvent was deoxygenated by bubbling with nitrogen
for 20 minutes. The solution was then irradiated in a micro-
wave at 100 °C for 4 hours. The resulting solution was
quenched with water (15 mL), and extracted with EtOAc
(2 × 10 mL). The organic phase was washed with concentrated
sodium bicarbonate solution (2 × 15 mL) water (2 × 15 mL),
and brine (2 × 15 mL), before being concentrated to a solid
under reduced pressure. This solid material was then re-
dissolved in dichloromethane (0.5 mL) and trifluoroacetic acid
(0.50 mL, 6.5 mmol) was added. The solution was then stirred
in inert atmosphere for 4 hours, before being diluted with
dichloromethane (15 mL). The solution was then washed with
concentrated sodium bicarbonate solution (2 × 30 mL), taking
care due to the production of gas as the solution is neutral-
ised. The organic phase was then concentrated to a solid
under reduced pressure. This solid was then purified to the
desired product by mass-directed auto purification.
Dimethyl((2S,2′S)-((2S,2′S)-2,2′-(5,5′-([1,1′-biphenyl]-4,4′-diyl)
bis(1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-
oxobutane-2,1-diyl))dicarbamate (1). 1H NMR (500 MHz,
CD3OD) 7.73 (4H, d, J 8.2 Hz, ArH), 7.66 (4H, d, J 8.0, Ar), 7.37
(2H, s, ArH), 5.19 (2H, dd, J 8.0 Hz, 6.3 Hz, CH), 4.24 (2H, d,
J 7.4 Hz, CH), 4.05–3.95 (2H, m, CHAB), 3.92–3.84 (2H, m,
CHAB), 3.66 (6H, s, CH3), 2.41–2.17 (6H, m, CH2, CHAB),
2.11–2.04 (4H, m, CHAB, CH), 0.93 (12H, dd, J 22.0 Hz, 6.8 Hz,
i-PrCH3);
13C NMR (126 MHz, CD3OD) 172.0 (CO), 158.0
(NCN), 149.6 (OC(O)N), 139.0 (ArC), 136.1 (ArC), 130.9 (ArC),
126.6 (ArCH), 125.0 (ArCH), 116.2 (ArCH), 58.4 (CH), 54.8 (CH),
51.3 (CH3), 47.4 (CH2), 30.9 (CH2), 30.1 (CH), 24.7 (CH2), 18.4
(i-PrCH3), 17.0 (i-PrCH3); IR (neat, νmax, cm
−1) 2964 (w), 2875
(w), 1705 (s), 1632 (s), 1446 (s), 1393 (s), 1258 (w), 1035 (m),
829 (m), 773 (m); HRMS (ESI): calcd for C40H51N8O6 [M + H]
+
739.3926, found 739.3937; [α]D −170.0 (c 0.6 in CHCl3,
T 22.2 °C).
Dimethyl((2S,2′S)-((2S,2′S)-2,2′-(5,5′-(1,4-phenylene)bis(1H-
imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxo-
butane-2,1-diyl))dicarbamate (14). 1H NMR (500 MHz,
CD3OD) 7.88 (4H, s, Ar), 7.48 (2H, s, ArH), 5.29–5.19 (2H, m,
CH), 4.29–4.17 (2H, m, CH), 4.14–3.97 (2H, m, CHAB),
3.93–3.77 (2H, m, CHAB), 3.66 (6H, s, CH3), 2.60–2.46 (CHAB, m,
2H), 2.32–1.95 (8H, m, CHAB, CH2, CH), 0.96–0.85 (12H, m,
i-PrCH3);
13C NMR (126 MHz, CD3OD) 172.7 (CO), 158.1
(NCN), 149.4 (OC(O)N), 147.5 (ArC), 126.0 (ArC), 118.7 (ArCH),
115.3 (ArCH), 58.5 (CH), 53.7 (CH), 53.2 (CH2), 51.4 (CH3), 29.8
(CH), 24.9 (CH2), 18.4 (CH2), 16.7 (i-PrCH3); IR (neat, νmax,
cm−1) 3284 (bw), 2962 (w), 1711 (s), 1625 (s), 1521 (s), 1444 (s),
1370 (w), 1264 (s), 1192 (m), 1098 (m), 1037 (m), 846 (m), 734
(s); HRMS (ESI): calcd for C34H47N8O6 [M + H]
+ 663.3613,
found 663.3608; [α]D −288.6 (c 0.3 in CHCl3, T 22.6 °C).
Dimethyl((2S,2′S)-((2S,2′S)-2,2′-(5,5′-((E)-ethene-1,2-diylbis(4,1-
phenylene))bis(1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))
bis(3-methyl-1-oxobutane-2,1-diyl))dicarbamate (15). 1H NMR
(500 MHz, CD3OD) 8.16 (2H, s, alkeneH), 7.92 (2H, d, J 8.6 Hz,
ArCH), 7.82 (2H, d, J 8.3 Hz, ArCH), 7.66 (2H, s, ArCH), 5.24
(2H, dd, J 8.1 Hz, 6.2 Hz, CH), 4.26 (2H, d, J 7.3 Hz, CH),
4.09–4.02 (2H, m, CHAB), 3.97–3.81 (2H, m, CHAB), 3.67 (6H, s,
CH3), 2.52–2.41 (2H, m, CHAB), 2.32–2.02 (8H, m, CHAB, CH2,
CH), 0.94 (12H, dd, J 24.3, 6.7, i-PrCH3);
13C NMR (126 MHz,
CD3OD) 172.4 (CO), 163.2 (NCN), 158.1 (ArC), 149.6 (OC(O)N),
133.0 (ArC), 128.5 (ArC), 125.0 (alkeneCH), 123.7 (ArCH), 123.0
(ArCH), 115.8 (ArCH), 58.5 (CH), 54.4 (CH), 51.4 (CH3), 47.5
(CH2), 30.9 (CH2), 30.0 (CH), 24.8 (CH2), 18.4 (CH3), 16.9
(i-PrCH3); IR (neat, νmax, cm
−1) 2966 (w), 2876 (w), 1701 (s),
1631 (s), 1521 (m), 1443 (m), 1264 (w), 1201 (s), 1132 (m), 1033
(w), 799 (w), 719 (m); HRMS (ESI): calcd for C42H53N8O6
[M + H]+ 765.4083, found 765.4118; [α]D −538.3 (c 0.3 in
CHCl3, T 22.6 °C).
Dimethyl((2S,2′S)-((2S,2′S)-2,2′-(5,5′-(naphthalene-2,6-diyl)
bis(1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-
1-oxobutane-2,1-diyl))dicarbamate (16). 1H NMR (500 MHz,
CD3OD) 7.64–7.54 (4H, m, ArH), 7.41 (2H, s, ArH), 7.20–7.13
(2H, m, ArCH), 5.19 (2H, t, J 7.0 Hz, CH), 4.24 (2H, d, J 7.3 Hz,
CH), 4.06–3.97 (2H, m, CHAB), 3.92–3.83 (2H, m, 22/26-CHAB),
3.66 (6H, s, CH3), 2.43–2.32 (2H, m, CHAB), 2.31–1.97 (8H,
m, CHAB, CH2, CH), 0.93 (12H, dd, J 22.8 Hz, 6.9 Hz, i-PrCH3);
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13C NMR (126 MHz, CD3OD) 172.2 (CO), 158.0 (NCN), 149.4
(OC(O)N), 136.7 (ArC), 135.6 (ArC), 130.0 (ArC), 127.8 (ArCH),
126.7 (ArCH), 124.8 (ArCH), 115.9 (ArCH), 58.4 (CH), 54.6 (CH),
51.4 (CH3), 47.5 (CH2), 30.9 (CH2), 30.1 (CH), 24.7 (CH2), 18.4
(i-PrCH3), 16.9 (i-PrCH3); IR (neat, νmax, cm
−1) 3287 (bw), 2962
(w), 2875 (w), 1711 (s), 1628 (w), 1517 (m) 1443 (m), 1370 (w),
1264 (m), 1181 (m), 1131 (m), 1035 (m), 947 (w), 841 (m), 775
(m), 732 (s); HRMS (ESI): calcd for C38H49N8O6 [M + H]
+
713.3770, found 713.3779; [α]D −222.1 (c 0.6 in CHCl3,
T 22.1 °C).
Dimethyl((2S,2′S)-((2S,2′S)-2,2′-(5,5′-(oxybis(4,1-phenylene))
bis(1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-
1-oxobutane-2,1-diyl))dicarbamate (17). 1H NMR (500 MHz,
CD3OD) 8.13 (2H, s, NH), 7.68 (4H, d, J 8.1 Hz, ArH), 7.48 (2H,
s, ArH), 7.08 (4H, d, J 8.0 Hz, ArH), 5.20 (2H, t, J 7.1 Hz, CH),
4.24 (2H, d, J 7.2 Hz, CH), 4.09–3.99 (2H, m, CHAB), 3.92–3.82
(2H, m, CHAB), 3.66 (6H, s, CH3), 2.50–2.35 (2H, m, CHAB),
2.31–1.97 (8H, m, CHAB, CH2, CH), 0.91 (12H, dd, J 20.4 Hz,
6.8 Hz, i-PrCH3);
13C NMR (126 MHz, CD3OD) 172.3 (CO),
163.5 (NCN), 158.1 (OC(O)N), 156.9 (ArC), 149.1 (ArC), 134.9
(ArC), 126.6 (ArCH), 118.9 (ArCH), 114.8 (ArCH), 58.4 (CH),
54.3 (CH), 51.4 (CH3), 47.5 (CH2), 30.9 (CH2), 30.0 (CH), 24.8
(CH2), 18.4 (i-PrCH3), 16.8 (i-PrCH3); IR (neat, νmax, cm
−1) 3294
(bw), 2962 (w), 2875 (w), 1712 (m), 1627 (s), 1497 (m), 1424
(m), 1237 (s), 1199 (m), 1198 9m), 1130 (m), 1033 (m), 798 (m),
733 (s), 701 (m); HRMS (ESI): calcd for C40H51N8O7 [M + H]
+
755.3875, found 755.3882; [α]D −114.3 (c 0.6 in CHCl3,
T 22.0 °C).
Methyl N-[(2S)-1-[(2S)-2-{5-[4-(5-{2-[(2S)-1-[(2S)-2-[(methoxy-
carbonyl)amino]-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imid-
azol-5-yl}-1,3-benzoxazol-2-yl)phenyl]-1H-imidazol-2-yl}pyrrolidin-
1-yl]-3-methyl-1-oxobutan-2-yl]carbamate (18). 1H NMR
(500 MHz, CD3OD) δ 8.33–8.20 (2H, m, ArH), 8.02 (1H, d, J 8.3
Hz, ArH), 7.94–7.84 (2H, m, ArH), 7.83–7.70 (2H, m, ArH),
7.72–7.59 (2H, m, ArH), 5.27–5.18 (2H, m, CH), 4.25 (2H, t, J =
7.3 Hz, CH), 4.13–3.98 (2H, m, CHAB), 3.95–3.84 (2H, m, CHAB),
3.66 (6H, s, CH3), 2.57–2.35 (2H, m, CHAB), 2.32–2.02 (8H, m,
CHAB, CH2, CH), 0.99–0.89 (12H, m, iPrCH3);
13C NMR
(126 MHz, CD3OD 3) δ 173.7 (CO), 165.0 (ArC), 159.5 (OC(O)N),
152.9 (ArC), 152.4 (Ar–C), 152.0 (Ar–C), 151.5 (ArC), 150.3
(NCN), 136.6 (ArC), 136.0 (ArC), 129.3 (ArCH), 126.5 (ArCH),
124.5 (ArCH), 118.0 (ArCH), 117.5 (ArCH), 116.4 (ArCH), 112.5
(ArCH), 59.9 (CH), 55.4 (CH3), 52.8 (CH2), 49.0 (CH2), 32.4
(CH2), 31.5 (CH), 26.3 (CH2), 19.8 (iPrCH3), 18.3 (iPrCH3);
IR (neat, νmax, cm
−1) 3284 (bw), 2966 (w), 2875 (w), 1699 (m),
1628 (s), 1517 (m), 1424 (m), 1368 (w), 1265 (m), 1180 (s), 1132
(s), 1039 (m), 825 (m), 798 (m), 732 (s); HRMS (ESI): calcd for
C41H50N9O7 [M + H]
+ 780.3828, found 780.3804; [α]D −446.6
(c 0.3 in CHCl3, T 22.4 °C).
Methyl N-[(2S)-1-[(2S)-2-(5-{4-[(4-{2-[(2S)-1-[(2S)-2-[(methoxy-
carbonyl)amino]-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-
5-yl}phenyl)(methyl)carbamoyl]phenyl}-1H-imidazol-2-yl)pyrro-
lidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate (19). 1H NMR
(500 MHz, CDCl3) δ 7.51–7.39 (2H, m, ArH), 7.35–7.26 (2H, m,
ArH), 7.26–7.20 (2H, m, ArH), 7.15–7.04 (2H, m, ArH), 6.98 (2H,
d, J 8.2 Hz, ArH), 5.58 (2H, s, NH), 5.18 (2H, s, CH), 4.30 (2H, t,
J 8.1 Hz, CH), 3.90–3.77 (2H, m, CHAB), 3.74–3.63 (8H, m,
CHAB, CH3), 3.46 (3H, s, CH3), 2.35–2.11 (4H, m, CHAB, CHAB),
2.09–1.85 (6H, m, CHAB, CHAB, CH), 0.88–0.77 (12H, m,
i-PrCH3);
13C NMR (100 MHz, CDCl3) δ 172.6 (CO), 170.2 (CO),
157.1 (OC(O)N), 148.5 (NCN), 143.6 (ArC), 138.5 (ArC), 134.3
(ArC), 132.3 (ArC), 129.3 (ArCH), 127.1 (ArCH), 125.5 (ArCH),
124.6 (ArC), 123.9 (ArCH), 115.3 (ArCH), 57.7 (CH), 54.2 (CH),
52.3 (CH3), 47.8 (CH2), 38.4 (CH3), 30.8 (CH), 28.4 (CH2), 25.2
(CH2), 19.2 (i-PrCH3), 17.43 (i-PrCH3); IR (neat, νmax, cm
−1)
3227 (bw), 2958 (w), 1698 (s), 1630 (s), 1532 (m), 1445 (m),
1396 (m), 1203 (m), 1137 (m), 1038 (w), 847 (w); HRMS (ESI):
calcd for C41H50N9O7 [M + H]
+ 796.4141, found 796.4240;
[α]D −243.3 (c 0.6 in CHCl3, T 22.4 °C).
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